{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T08:10:04Z","timestamp":1718611804294},"reference-count":29,"publisher":"Pharmaceutical Society of Japan","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2016]]},"DOI":"10.1248\/bpb.b15-01021","type":"journal-article","created":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T22:05:28Z","timestamp":1464732328000},"page":"1000-1006","source":"Crossref","is-referenced-by-count":9,"title":["Effect of a Ferric Citrate Formulation, a Phosphate Binder, on Oxidative Stress in Chronic Kidney Diseases-Mineral and Bone Disorder Patients Receiving Hemodialysis: A Pilot Study"],"prefix":"10.1248","volume":"39","author":[{"given":"Motoko","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Nephrology, Akebono Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeyuki","family":"Miyamura","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Imafuku","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuna","family":"Tominaga","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Anraku","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Sojo University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keishi","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Sojo University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kadowaki","sequence":"additional","affiliation":[{"name":"Faculty of Clinical Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Ishima","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Okuda","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Akebono Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Akebono Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Akebono Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Otagiri","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Sojo University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, Whittier FC, Linfert DR, Galphin CM, Athreya BP, Nossuli AK, Chang IJ, Blumenthal SS, Manley J, Zeig S, Kant KS, Olivero JJ, Greene T, Dwyer JP, Collaborative Study Group. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. <i>J. Am. Soc. Nephrol.<\/i>, <b>26<\/b>, 493\u2013503 (2015).","DOI":"10.1681\/ASN.2014020212"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Nastou D, Fern\u00e1ndez-Fern\u00e1ndez B, Elewa U, Gonz\u00e1lez-Espinoza L, Gonz\u00e1lez-Parra E, Sanchez-Ni\u00f1o MD, Ortiz A. Next-generation phosphate binders: focus on iron-based binders. <i>Drugs<\/i>, <b>74<\/b>, 863\u2013877 (2014).","DOI":"10.1007\/s40265-014-0224-6"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Yokoyama K, Hirakata H, Akiba T, Sawada K, Kumagai Y. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. <i>Am. J. Nephrol.<\/i>, <b>36<\/b>, 478\u2013487 (2012).","DOI":"10.1159\/000344008"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Chertow GM, Hirakata H. A randomized trial of JTT-751 <i>versus<\/i> sevelamer hydrochloride in patients on hemodialysis. <i>Nephrol. Dial. Transplant.<\/i>, <b>29<\/b>, 1053\u20131060 (2014).","DOI":"10.1093\/ndt\/gft483"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Block GA. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. <i>Clin. J. Am. Soc. Nephrol.<\/i>, <b>9<\/b>, 543\u2013552 (2014).","DOI":"10.2215\/CJN.05170513"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Hirakata H. JTT-751 for treatment of patients with hyperphosphatemia on peritoneal dialysis. <i>Nephron Clin. Pract.<\/i>, <b>128<\/b>, 135\u2013140 (2014).","DOI":"10.1159\/000366482"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Chertow GM, Hirakata H. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis. <i>J. Ren. Nutr.<\/i>, <b>24<\/b>, 261\u2013267 (2014).","DOI":"10.1053\/j.jrn.2014.03.006"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, Wolf M, Chertow GM. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3\u20135. <i>Am. J. Kidney Dis.<\/i>, <b>65<\/b>, 728\u2013736 (2015).","DOI":"10.1053\/j.ajkd.2014.10.014"},{"key":"9","unstructured":"9) Nakanishi T, Hasuike Y, Nanami M, Yahiro M, Kuragano T. Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited. <i>Nephrol. Dial. Transplant<\/i>., Jul 3, pii: gfv268 (2015). [Epub ahead of print]."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M, Marcus S, Faich G. Iron administration and clinical outcomes in hemodialysis patients. <i>J. Am. Soc. Nephrol.<\/i>, <b>13<\/b>, 734\u2013744 (2002).","DOI":"10.1681\/ASN.V133734"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Rooyakkers TM, Stroes ES, Kooistra MP, van Faassen EE, Hider RC, Rabelink TJ, Marx JJ. Ferric saccharate induces oxygen radical stress and endothelial dysfunction <i>in vivo<\/i>. <i>Eur. J. Clin. Invest.<\/i>, <b>32<\/b> (Suppl. 1), 9\u201316 (2002).","DOI":"10.1046\/j.1365-2362.2002.0320s1009.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. <i>Clin. J. Am. Soc. Nephrol.<\/i>, <b>1<\/b> (Suppl. 1), S19\u2013S23 (2006).","DOI":"10.2215\/CJN.01420406"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kletzmayr J, H\u00f6rl WH, Kletzmayr J, H\u00f6rl WH. Iron overload and cardiovascular complications in dialysis patients. <i>Nephrol. Dial. Transplant.<\/i>, <b>17<\/b> (Suppl. 2), 25\u201329 (2002).","DOI":"10.1093\/ndt\/17.suppl_2.25"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Anraku M, Kitamura K, Shinohara A, Adachi M, Suenaga A, Maruyama T, Miyanaka K, Miyoshi T, Shiraishi N, Nonoguchi H, Otagiri M, Tomita K. Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. <i>Kidney Int.<\/i>, <b>66<\/b>, 841\u2013848 (2004).","DOI":"10.1111\/j.1523-1755.2004.00813.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Anraku M, Kitamura K, Shintomo R, Takeuchi K, Ikeda H, Nagano J, Ko T, Mera K, Tomita K, Otagiri M. Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: A pilot study. <i>Clin. Biochem.<\/i>, <b>41<\/b>, 1168\u20131174 (2008).","DOI":"10.1016\/j.clinbiochem.2008.07.007"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Nagumo K, Tanaka M, Chuang VT, Setoyama H, Watanabe H, Yamada N, Kubota K, Tanaka M, Matsushita K, Yoshida A, Jinnouchi H, Anraku M, Kadowaki D, Ishima Y, Sasaki Y, Otagiri M, Maruyama T. Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stress-related chronic diseases. <i>PLoS ONE<\/i>, <b>9<\/b>, e85216 (2014).","DOI":"10.1371\/journal.pone.0085216"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Kubota K, Nakayama A, Takehana K, Kawakami A, Yamada N, Suzuki E. A simple stabilization method of reduced albumin in blood and plasma for the reduced\/oxidized albumin ratio measurement. <i>Int. J. Biomed. Sci.<\/i>, <b>5<\/b>, 293\u2013301 (2009).","DOI":"10.59566\/IJBS.2009.5293"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Witko-Sarsat V, Friedlander M, Capeill\u00e8re-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. <i>Kidney Int.<\/i>, <b>49<\/b>, 1304\u20131313 (1996).","DOI":"10.1038\/ki.1996.186"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Anraku M, Takeuchi K, Watanabe H, Kadowaki D, Kitamura K, Tomita K, Kuniyasu A, Suenaga A, Maruyama T, Otagiri M. Quantitative analysis of cysteine-34 on the anitioxidative properties of human serum albumin in hemodialysis patients. <i>J. Pharm. Sci.<\/i>, <b>100<\/b>, 3968\u20133976 (2011).","DOI":"10.1002\/jps.22571"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Garneata L. Intravenous iron, inflammation, and oxidative stress: is iron a friend or an enemy of uremic patients? <i>J. Ren. Nutr.<\/i>, <b>18<\/b>, 40\u201345 (2008).","DOI":"10.1053\/j.jrn.2007.10.009"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Witko-Sarsat V, Friedlander MA, Nguyen Khoa T, Capeill\u00e8re-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Dr\u00fceke T, Descamps-Latscha B. Advanced oxidation protein products (AOPP) as novel mediators of inflammation and monocyte activation in chronic renal failure. <i>J. Immunol.<\/i>, <b>161<\/b>, 2524\u20132532 (1998).","DOI":"10.4049\/jimmunol.161.5.2524"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Maruyama Y, Nakayama M, Yoshimura K, Nakano H, Yamamoto H, Yokoyama K, Lindholm B. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2\u2032-deoxyguanosine levels. <i>Nephrol. Dial. Transplant.<\/i>, <b>22<\/b>, 1407\u20131412 (2007).","DOI":"10.1093\/ndt\/gfl789"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Yoshimura K, Nakano H, Yokoyama K, Nakayama M. High iron storage levels are associated with increased DNA oxidative injury in patients on regular hemodialysis. <i>Clin. Exp. Nephrol.<\/i>, <b>9<\/b>, 158\u2013163 (2005).","DOI":"10.1007\/s10157-005-0354-y"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Dr\u00fceke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. <i>Circulation<\/i>, <b>106<\/b>, 2212\u20132217 (2002).","DOI":"10.1161\/01.CIR.0000035250.66458.67"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Terawaki H, Matsuyama Y, Matsuo N, Ogura M, Mitome J, Hamaguchi A, Terada T, Era S, Hosoya T. A lower level of reduced albumin induces serious cardiovascular incidence among peritoneal dialysis patients. <i>Clin. Exp. Nephrol.<\/i>, <b>16<\/b>, 629\u2013635 (2012).","DOI":"10.1007\/s10157-012-0610-x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Terawaki H, Era S, Nakayama M, Hosoya T. Decrease in reduced-form albumin among chronic kidney disease patients: new insights in cardiovascular complications. <i>Ther. Apher. Dial.<\/i>, <b>15<\/b>, 156\u2013160 (2011).","DOI":"10.1111\/j.1744-9987.2010.00889.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Matsuyama Y, Hayashi T, Terawaki H, Negawa T, Terada T, Okano Y, Era S. Human astrocytes and aortic endothelial cells actively convert the oxidized form of albumin to the reduced form: reduced albumin might participate in redox regulation of nerve and blood vessel systems. <i>J. Physiol. Sci.<\/i>, <b>59<\/b>, 207\u2013215 (2009).","DOI":"10.1007\/s12576-009-0028-8"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Lim PS, Jeng Y, Wu MY, Pai MA, Wu TK, Liu CS, Chen CH, Kuo YC, Chien SW, Chen HP. Serum oxidized albumin and cardiovascular mortality in normoalbuminemic hemodialysis patients: a cohort study. <i>PLoS ONE<\/i>, <b>8<\/b>, e70822 (2013).","DOI":"10.1371\/journal.pone.0070822"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Domenicali M, Baldassarre M, Giannone FA, Naldi M, Mastroroberto M, Biselli M, Laggetta M, Patrono D, Bertucci C, Bernardi M, Caraceni P. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. <i>Hepatology<\/i>, <b>60<\/b>, 1851\u20131860 (2014).","DOI":"10.1002\/hep.27322"}],"container-title":["Biological &amp; Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/39\/6\/39_b15-01021\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T07:31:40Z","timestamp":1718609500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/39\/6\/39_b15-01021\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b15-01021","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}